Zymeworks Inc. (ZYME)
Zymeworks Statistics
Share Statistics
Zymeworks has 69.58M shares outstanding. The number of shares has increased by -1.6% in one year.
| Shares Outstanding | 69.58M |
| Shares Change (YoY) | -1.6% |
| Shares Change (QoQ) | 1.02% |
| Owned by Institutions (%) | 87.59% |
| Shares Floating | 67.3M |
| Failed to Deliver (FTD) Shares | 928 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 5.41M, so 7.77% of the outstanding shares have been sold short.
| Short Interest | 5.41M |
| Short % of Shares Out | 7.77% |
| Short % of Float | 10.09% |
| Short Ratio (days to cover) | 9.29 |
Valuation Ratios
The PE ratio is -9.05 and the forward PE ratio is -12.4. Zymeworks's PEG ratio is 0.
| PE Ratio | -9.05 |
| Forward PE | -12.4 |
| PS Ratio | 14.55 |
| Forward PS | 3.9 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zymeworks.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.4 |
| Quick Ratio | 3.4 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $272.51K |
| Profits Per Employee | $-438.2K |
| Employee Count | 280 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 6.08M |
| Effective Tax Rate | -5.22% |
Stock Price Statistics
The stock price has increased by 32.99% in the last 52 weeks. The beta is 1.17, so Zymeworks's price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | 32.99% |
| 50-Day Moving Average | 12.58 |
| 200-Day Moving Average | 12.71 |
| Relative Strength Index (RSI) | 49.31 |
| Average Volume (20 Days) | 627.64K |
Income Statement
In the last 12 months, Zymeworks had revenue of 76.3M and earned -122.69M in profits. Earnings per share was -1617.67.
| Revenue | 76.3M |
| Gross Profit | 76.3M |
| Operating Income | -137.11M |
| Net Income | -122.69M |
| EBITDA | -137.11B |
| EBIT | -119.82M |
| Earnings Per Share (EPS) | -1617.67 |
Balance Sheet
The company has 66.1B in cash and 18.48B in debt, giving a net cash position of 47.63B.
| Cash & Cash Equivalents | 66.1B |
| Total Debt | 18.48B |
| Net Cash | 47.63B |
| Retained Earnings | -830.34B |
| Total Assets | 463.09M |
| Working Capital | 212.16M |
Cash Flow
In the last 12 months, operating cash flow was -110.04B and capital expenditures 0, giving a free cash flow of -110.04B.
| Operating Cash Flow | -110.04B |
| Capital Expenditures | 0 |
| Free Cash Flow | -110.04B |
| FCF Per Share | -1450.87 |
Margins
Gross margin is 100%, with operating and profit margins of -179.69% and -160.8%.
| Gross Margin | 100% |
| Operating Margin | -179.69% |
| Pretax Margin | -152.82% |
| Profit Margin | -160.8% |
| EBITDA Margin | -179689.14% |
| EBIT Margin | -179.69% |
| FCF Margin | -144217.87% |
Dividends & Yields
ZYME does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ZYME is $18.5, which is 60.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.5 |
| Price Target Difference | 60.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.06 |
| Piotroski F-Score | 3 |